Xcelience Opens Expanded Tampa, Florida, Headquarters
11/02/2015
The company provides services from preformulation through global clinical supplies packaging and distribution to international pharmaceutical and biotechnology clients for Phases I-IV.
According to the firm, the building houses preformulation and formulation development labs and suites, as well as analytical and stability services, as well as the executive headquarters. Build out plans for a new analytical lab is developing. The company's previous headquarters on West Laurel Street in Tampa is transitioning to provide clinical trial and small-scale commercial manufacturing.
"This year marks a rapid expansion in our service offerings," says Derek Hennecke, President/CEO. "In July we integrated with Powdersize because so many of our clients needed industry-leading micronization services. Now, with this new facility, we will be able to increase capacity throughout the organization. More capacity means we can be more flexible in dealing with changing client needs and timelines."
Project Announcements
AESC Expands Florence, South Carolina, Operations
03/28/2024
Alticor Expands Ada Township, Michigan, Operations
03/27/2024
Eastman Plans Longview, Texas, Production Operations
03/27/2024
DHL Supply Chain-Vantage Data Centers NV11 Plan Nevada Operations
03/26/2024
Big Jet Expands Pittsburgh, Pennsylvania, Operations
03/26/2024
Landmark Ceramics UST Expands Mt. Pleasant, Tennessee, Operations
03/25/2024
Most Read
-
2023's Leading Metro Locations: Hotspots of Economic Growth
Q4 2023
-
2023 Top States for Doing Business Meet the Needs of Site Selectors
Q3 2023
-
The Logistics Analysis That Drives Industrial Site Selection
Q4 2023
-
Manufacturing Momentum Is Building
Q1 2024
-
Technology’s Influence on Workforce Development
Workforce Q4 2023
-
38th Annual Corporate Survey: Are Unrealized Predictions of an Economic Slump Leading Small to Mid-Size Companies to Put Off Expansion Plans?
Q1 2024
-
37th Annual Corporate Survey: Economic Pressures Exerting Greatest Effect on Decision-Makers
Q1 2023